Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
161Tb-SibuDAB in Metastatic Prostate Cancer
NCT06343038Phase 1Recruiting
- Sponsor
- University Hospital Basel
- Start
- Feb 2024
- Primary completion
- Jun 2028
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of terbium-161 SibuDAB in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by University Hospital Basel. Primary endpoints: Tumour absorbed dose at 168 hours and Identification of the optimal biological dose of 161Tb-SibuDAB at 12 months. Started Feb 2024; status: recruiting.
02
Drugs
terbium-161 SibuDAB
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06343038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343038.